دورية أكاديمية
Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study
| العنوان: | Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study |
|---|---|
| المؤلفون: | Fontán-Vela, Mario, Hernando Sebastian, Victoria, Olmedo, Carmen, Coma, Ermengol, Martínez, Montse, Moreno-Perez, David, Lorusso, Nicola, Vázquez Torres, María, Barbas del Buey, José Francisco, Roig-Sena, Javier, Pastor, Eliseo, Galmés Truyols, Antònia, Artigues Serra, Francisca, Sancho Martínez, Rosa María, Latasa Zamalloa, Pello, Pérez Martínez, Olaia, Vázquez Estepa, Ana, García Rojas, Amós José, Barreno Estévez, Ana Isabel, Sánchez-Migallón Naranjo, Alonso, Pérez Martín, Jaime Jesús, Peces Jiménez, Pilar, Morales Romero, Raquel, Castilla, Jesús, García Cenoz, Manuel, Huerta Huerta, Marta, Boone, An Lieve Dirk, Macías Ortiz, María José, Álvarez Río, Virginia, Rodríguez Recio, María Jesús, Merino Díaz, María, Berradre Sáenz, Belén, Villegas-Moreno, María Teresa, Limia, Aurora, Diaz Franco, Asuncion, Monge Corella, Susana, Spanish MPOX vaccine effectiveness study group, Jarrin-Vera, Inmaculada |
| بيانات النشر: | Oxford University Press |
| سنة النشر: | 2024 |
| المجموعة: | REPISALUD (REPositorio Institucional en SALUD del Instituto de Salud Carlos III - ISCIII) |
| مصطلحات موضوعية: | mpox, Monkeypox, Vaccine effectiveness, MVA-BN vaccine, Pre-exposure prophylaxis |
| الوصف: | Background: With over 7,500 cases notified since April 2022, Spain has experienced the highest incidence of mpox in Europe. From July 12th onwards, the Modified Vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine was offered as pre-exposure prophylaxis for individuals at high-risk of mpox, including those receiving pre-exposure prophylaxis for HIV (HIV-PrEP). Our aim was to assess the effectiveness of one dose of MVA-BN vaccine as pre-exposure against mpox virus (MPXV) infection in persons on HIV-PrEP. Methods: We conducted a national retrospective cohort study between July 12 and December 12, 2022. Individuals ≥18 years, receiving HIV-PrEP as of July 12 and with no previous MPXV infection or vaccination were eligible. Each day, we matched individuals receiving a first dose of MVA-BN vaccine and unvaccinated controls of the same age group and region. We used a Kaplan-Meier estimator and calculate risk ratios (RR) and vaccine effectiveness (VE = 1-RR). Results: We included 5,660 matched pairs, with a median follow-up of 62 days (interquartile range 24-97). Mpox cumulative incidence was 5.6 per 1,000 (25 cases) in unvaccinated and 3.5 per 1,000 (18 cases) in vaccinated. No effect was found during days 0-6 post-vaccination (VE -38.3; 95% confidence interval (95%CI): -332.7; 46.4), but VE was 65% in ≥7 days (95%CI 22.9; 88.0) and 79% in ≥14 days (95%CI 33.3; 100.0) post-vaccination. Conclusions: One dose of MVA-BN vaccine offered protection against mpox in a most-at-risk population shortly after the vaccination. Further studies need to assess the VE of a second dose and the duration of protection over time. ; Sí |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1058-4838 1537-6591 |
| العلاقة: | https://doi.org/10.1093/cid/ciad645Test; Clin Infect Dis. 2024 Feb 17;78(2):476-483.; http://hdl.handle.net/20.500.12105/16837Test; Clinical Infectious Diseases |
| DOI: | 10.1093/cid/ciad645 |
| الإتاحة: | https://doi.org/20.500.12105/16837Test https://doi.org/10.1093/cid/ciad645Test https://hdl.handle.net/20.500.12105/16837Test |
| حقوق: | http://creativecommons.org/licenses/by/4.0Test/ ; Atribución 4.0 Internacional ; open access |
| رقم الانضمام: | edsbas.9B1607ED |
| قاعدة البيانات: | BASE |
| تدمد: | 10584838 15376591 |
|---|---|
| DOI: | 10.1093/cid/ciad645 |